drugset
drugset / Trial / NCT00479635

A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer

NCT00479635 ↗

Phase 2 Terminated 26 enrolled Cortice Biosciences, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of the study is to determine the response rate to TPI 287 in patients with metastatic, hormone-refractory prostate cancer who have had one prior taxane regimen.

Timeline

Start
2007-01
Primary completion
2008-08
Completion
2008-08

Outcome

Outcome not reported

Stopped (Enrollment): “Sponsor could no longer support; enrollment stopped August 2008.”

Drugs

EvaluationDrugModalityDoseRoute
Subject TPI 287 Small molecule 160 mg/m2 Intravenous

Indications

prostate cancer